OS Therapies Inc.

OS Therapies Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for osteosarcoma and other solid tumors. The company’s current work centers on oncology programs that aim to harness the immune system against cancers expressing HER2, including its lead immunotherapy candidate OST-HER2. OS Therapies also advances an antibody-drug conjugate platform designed to support targeted cancer therapy development. Its product pipeline is directed toward high-unmet-need cancers, particularly rare bone cancers and other HER2-related solid tumors. Based in Grasonville, Maryland, OS Therapies Inc. operates within the biotechnology sector as a development-stage company focused on investigational cancer treatments and platform technologies for future clinical use.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Paul A. Romness M.P.H.

Employees

4

Headquarters

Grasonville, MD, United States

Website

ostherapies.com